Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: A review
- PMID: 32112928
- DOI: 10.1016/j.ijpharm.2020.119181
Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: A review
Abstract
Complexation with cyclodextrins (CDs) has been widely and successfully used in pharmaceutical field, mainly for enhancing solubility, stability and bioavailability of a variety of drugs. However, some important drawbacks, including rapid removal from the bloodstream after in vivo administration, or possible replacement, in biological media, of the entrapped drug moieties by other molecules with higher affinity for the CD cavity, can limit the CDs effectiveness as drug carriers. This review is focused on combined strategies simultaneously exploiting CD complexation, and loading of the complexed drug into various colloidal carriers (liposomes, niosomes, polymeric nanoparticles, lipid nanoparticles, nanoemulsions, micelles) which have been investigated as a possible means for circumventing the problems associated with both such carriers, when used separately, and join their relative benefits in a unique delivery system. Several examples of applications have been reported, to illustrate the possible advantages achievable by such a dual strategy, depending on the CD-nanocarrier combination, and mainly resulting in enhanced performance of the delivery system and improved biopharmaceutical properties and therapeutic efficacy of drugs. The major problems and/or drawbacks found in the development of such systems, as well as the (rare) case of failures in achieving the expected improvements have also been highlighted.
Keywords: Cyclodextrin complexation; Drug-in cyclodextrin-in nanocarrier; Enhanced stability; Improved drug bioavailability; Increased entrapment efficiency; carboxymethyl-β-cyclodextrin (CAS 218269-34-2); chitosan (CAS 9012-76-4); hydroxypropyl-β-cyclodextrin (CAS 128446-35-5); methyl-β-cyclodextrin (128446-36-6); phospholipid (CAS 123465-35-0); poly(lactyde-co-glycolide (PLGA) copolymers (CAS 26780-50-7); sulfobutylether-β-cyclodextrin (CAS 182410-00-0); β-cyclodextrin (CAS 7585-39-9); γ-cyclodextrin (CAS 17465-86-0).
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems.J Pharm Sci. 2018 Jul;107(7):1741-1753. doi: 10.1016/j.xphs.2018.03.021. Epub 2018 Apr 3. J Pharm Sci. 2018. PMID: 29625157 Review.
-
Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation.Int J Pharm. 2016 Dec 30;515(1-2):684-691. doi: 10.1016/j.ijpharm.2016.11.013. Epub 2016 Nov 5. Int J Pharm. 2016. PMID: 27825863
-
Cyclodextrin complexes: Perspective from drug delivery and formulation.Drug Dev Res. 2018 Aug;79(5):201-217. doi: 10.1002/ddr.21452. Drug Dev Res. 2018. PMID: 30188584 Review.
-
A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications.Nanomedicine (Lond). 2014 May;9(6):877-94. doi: 10.2217/nnm.14.41. Nanomedicine (Lond). 2014. PMID: 24981652 Review.
-
Drug-Encapsulated Cyclodextrin Nanosponges.Methods Mol Biol. 2021;2207:247-283. doi: 10.1007/978-1-0716-0920-0_19. Methods Mol Biol. 2021. PMID: 33113141 Review.
Cited by
-
Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.Pharmaceutics. 2021 Dec 10;13(12):2131. doi: 10.3390/pharmaceutics13122131. Pharmaceutics. 2021. PMID: 34959412 Free PMC article. Review.
-
Applications of Cyclodextrin-Based Drug Delivery Systems in Inflammation-Related Diseases.Pharmaceutics. 2025 Mar 17;17(3):378. doi: 10.3390/pharmaceutics17030378. Pharmaceutics. 2025. PMID: 40143041 Free PMC article. Review.
-
Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv.Front Bioeng Biotechnol. 2022 Mar 24;10:866275. doi: 10.3389/fbioe.2022.866275. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35402395 Free PMC article.
-
The development of an innovative method to improve the dissolution performance of rivaroxaban.Heliyon. 2024 Jun 15;10(12):e33162. doi: 10.1016/j.heliyon.2024.e33162. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 39021978 Free PMC article.
-
A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.Sci Rep. 2021 Jun 22;11(1):13027. doi: 10.1038/s41598-021-92447-x. Sci Rep. 2021. PMID: 34158544 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources